RESUMEN
BACKGROUND: Pregnant women are at a high-risk of influenza infection. We have previously reported a low influenza vaccination coverage rate (4.0%) in Korea during the 2006-2007 influenza season. We conducted follow-up studies in 2011-2012 and 2018-2019 to observe changes in influenza vaccination coverage. METHODS: Women who delivered at Inha University Hospital (Incheon, Korea) in 2011-2012 and 2018-2019 were enrolled in the study. We surveyed the rate of influenza vaccination, perception scores, and related factors through telephonic interviews and compared the results from 2011-2012 and 2018-2019 with those from 2006-2007. RESULTS: The number of survey respondents was 227 in 2006-2007, 152 in 2011-2012, and 171 in 2018-2019. The rate of vaccination coverage increased from 4.0% in 2006-2007 to 42.0% in 2011-2012 and 59.3% in 2018-2019. Perception scores also increased progressively from 3.8 in 2006-2007 to 4.2 in 2011-2012 and 5.1 in 2018-2019. Physician recommendations for influenza vaccination also increased from 4.8% in 2006-2007 to 36.8% in 2011-2012 and 49.7% in 2018-2019. The most common reason for not getting vaccinated was the lack of awareness of influenza vaccination during pregnancy (36.9%). The perception scores and physician recommendation rates were significantly lower for unvaccinated women (3.87 and 8.4%, respectively) than for vaccinated women (5.14 and 69.1%, respectively). CONCLUSION: The influenza vaccination coverage rate in pregnant women has increased significantly since our study in 2006-2007. However, further improvement in the coverage rate is needed. There is a need for active and comprehensive publicity and education regarding this issue among physicians and pregnant women.
Asunto(s)
Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Mujeres Embarazadas/psicología , Vacunación/estadística & datos numéricos , Adulto , Consejo , Femenino , Humanos , Gripe Humana/inmunología , Entrevistas como Asunto , Percepción , Embarazo , República de Corea , Encuestas y CuestionariosRESUMEN
BACKGROUND: The spleen contains immune cells and exhibits a pattern of infarction different from other organs; as such, splenic infarction (SI) may provide important clues to infection. However, the nature of the relationship between SI and infectious disease(s) is not well understood. Accordingly, this retrospective study investigated the relationship between SI and infection. METHODS: Hospital records of patients with SI, who visited Inha University Hospital (Incheon, Republic of Korea) between January 2008 and December 2018, were reviewed. Patient data regarding clinical presentation, causative pathogens, risk factors, and radiological findings were collected and analyzed. RESULTS: Of 353 patients with SI, 101 with infectious conditions were enrolled in this study, and their data were analyzed to identify associations between SI and infection. Ten patients were diagnosed with infective endocarditis (IE), and 26 exhibited bacteremia without IE. Twenty-seven patients experienced systemic infection due to miscellaneous causes (negative result on conventional automated blood culture), including the following intracellular organisms: parasites (malaria [n = 12], babesiosis [n = 1]); bacteria (scrub typhus [n = 5]); viruses (Epstein-Barr [n = 1], cytomegalovirus [n = 1]); and unidentified pathogen[s] (n = 7). Splenomegaly was more common among patients with miscellaneous systemic infection; infarction involving other organs was rare. Thirty-eight patients had localized infections (e.g., respiratory, intra-abdominal, or skin and soft tissue infection), and most (35 of 38) had other risk factors for SI. CONCLUSIONS: In this study, various infectious conditions were found to be associated with SI, and intracellular organisms were the most common causative pathogens. Further studies are needed to examine other possible etiologies and the underlying pathophysiological mechanisms.
Asunto(s)
Bacteriemia/epidemiología , Infecciones por Citomegalovirus/epidemiología , Citomegalovirus/aislamiento & purificación , Endocarditis/epidemiología , Infecciones por Virus de Epstein-Barr/epidemiología , Herpesvirus Humano 4/aislamiento & purificación , Malaria Vivax/epidemiología , Orientia tsutsugamushi/aislamiento & purificación , Plasmodium vivax/aislamiento & purificación , Tifus por Ácaros/epidemiología , Infarto del Bazo/epidemiología , Adulto , Anciano , Cultivo de Sangre , Comorbilidad , Infecciones por Citomegalovirus/virología , Endocarditis/microbiología , Infecciones por Virus de Epstein-Barr/virología , Femenino , Hospitales Universitarios , Humanos , Malaria Vivax/parasitología , Masculino , Persona de Mediana Edad , República de Corea , Estudios Retrospectivos , Factores de Riesgo , Tifus por Ácaros/microbiologíaRESUMEN
BACKGROUND: Henoch-Schönlein purpura (HSP) may be caused by several allergens. However, to date, HSP caused by Orientia tsutsugamushi has not been reported. Here, we report an unusual rash with features of HSP caused by Orientia tsutsugamushi. CASE PRESENTATION: A man visited a tertiary hospital with bilateral symmetrical purpura and fever. He presented with an eschar in the left popliteal fossa and proteinuria. He was diagnosed with tsutsugamushi disease by indirect fluorescent antibody and positive polymerase chain reaction tests. Purpura biopsy demonstrated a feature of leukocytoclastic vasculitis and IgA deposition in dermal vessels, indicative of HSP. CONCLUSIONS: When examining patients with unique rashes, such as in this case, we suggest investigating out-door activities and evidence of mite bites. Furthermore, differential diagnosis of tsutsugamushi disease should be considered when necessary.
Asunto(s)
Vasculitis por IgA/diagnóstico , Orientia tsutsugamushi/aislamiento & purificación , Tifus por Ácaros/diagnóstico , Antibacterianos/uso terapéutico , Biopsia , Diagnóstico Diferencial , Humanos , Vasculitis por IgA/tratamiento farmacológico , Vasculitis por IgA/microbiología , Vasculitis por IgA/patología , Masculino , Persona de Mediana Edad , Orientia tsutsugamushi/genética , Orientia tsutsugamushi/inmunología , Tifus por Ácaros/tratamiento farmacológico , Tifus por Ácaros/microbiología , Tifus por Ácaros/patología , Piel/patología , Resultado del TratamientoRESUMEN
A comprehensive understanding of the geographic distribution of the tick-borne encephalitis virus (TBEV) complex is necessary due to increasing transboundary movement and cross-reactivity of serological tests. This review was conducted to identify the geographic distribution of the TBEV complex, including TBE virus, Alkhurma haemorrhagic fever virus, Kyasanur forest disease virus, louping-ill virus, Omsk haemorrhagic fever virus, and Powassan virus. Published reports were identified using PubMed, EMBASE, and the Cochrane library. In addition to TBEV complex case-related studies, seroprevalence studies were also retrieved to assess the risk of TBEV complex infection. Among 1406 search results, 314 articles met the inclusion criteria. The following countries, which are known to TBEV epidemic region, had conducted national surveillance studies: Austria, China, Czech, Denmark, Estonia, Finland, Germany, Hungary, Italy, Latvia, Norway, Poland, Romania, Russia, Switzerland, Sweden, Slovenia, and Slovakia. There were also studies/reports on human TBEV infection from Belarus, Bulgaria, Croatia, France, Japan, Kyrgyzstan, Netherland, and Turkey. Seroprevalence studies were found in some areas far from the TBEV belt, specifically Malaysia, Comoros, Djibouti, and Kenya. Kyasanur forest disease virus was reported in southwestern India and Yunnan of China, the Powassan virus in the United States, Canada, and east Siberia, Alkhurma haemorrhagic fever virus in Saudi Arabia and east Egypt, and Louping-ill virus in the United Kingdom, Ireland, and east Siberia. In some areas, the distribution of the TBEV complex overlaps with that of other viruses, and caution is recommended during serologic diagnosis. The geographic distribution of the TBEV complex appears to be wide and overlap of the TBE virus complex with other viruses was observed in some areas. Knowledge of the geographical distribution of the TBEV complex could help avoid cross-reactivity during the serologic diagnosis of these viruses. Surveillance studies can implement effective control measures according to the distribution pattern of these viruses.
Asunto(s)
Virus de la Encefalitis Transmitidos por Garrapatas/inmunología , Encefalitis Transmitida por Garrapatas/epidemiología , Enfermedades Endémicas/prevención & control , Animales , Reacciones Cruzadas , Virus de la Encefalitis Transmitidos por Garrapatas/clasificación , Virus de la Encefalitis Transmitidos por Garrapatas/aislamiento & purificación , Virus de la Encefalitis Transmitidos por Garrapatas/patogenicidad , Encefalitis Transmitida por Garrapatas/inmunología , Geografía , Humanos , Estudios Seroepidemiológicos , Pruebas Serológicas/normasRESUMEN
In malaria, splenic rupture is a serious complication potentially leading to death. Subcapsular hemorrhage of spleen is thought to be an impending sign of splenic rupture; however, the characteristics of subcapsular hemorrhage are not well known. We report 3 cases of subcapsular hemorrhage of the spleen in vivax malaria, with varying degrees of severity. Case 1 showed subcapsular hemorrhage without splenic rupture, was treated by antimalarial drug without any procedure. The healing process of the patient's spleen was monitored through 6 computed tomography follow-up examinations, over 118 days. Case 2 presented subcapsular hemorrhage with splenic rupture, treated only with an antimalarial drug. Case 3 showed subcapsular hemorrhage with splenic rupture and hypotension, treated using splenic artery embolization. They all recovered from subcapsular hemorrhage without any other complications. These 3 cases reveal the process of subcapsular hemorrhage leading to rupture and a potentially fatal outcome. The treatment plan of subcapsular hemorrhage should be determined carefully considering the vital signs, changes in hemoglobin, and bleeding tendency.
Asunto(s)
Hemorragia/etiología , Malaria Vivax/complicaciones , Enfermedades del Bazo/etiología , Adulto , Angiografía , Hemoperitoneo/diagnóstico por imagen , Hemoperitoneo/etiología , Hemorragia/diagnóstico por imagen , Humanos , Masculino , Bazo/diagnóstico por imagen , Enfermedades del Bazo/diagnóstico por imagen , Tomografía Computarizada por Rayos XRESUMEN
Bartonella henselae, a gram-negative bacterium, is a common causative agent of zoonotic infections. We report 5 culture-proven cases of B. henselae infection in South Korea. By alignment of the 16S rRNA sequences and multilocus sequencing typing analysis, we identified all isolates as B. henselae Houston-1 strain, which belongs to sequence type 1.
Asunto(s)
Infecciones por Bartonella/microbiología , Bartonella henselae/clasificación , ADN Bacteriano/genética , Adulto , Anciano , Técnicas de Tipificación Bacteriana , Infecciones por Bartonella/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Filogenia , ARN Ribosómico 16S/genética , República de Corea , Adulto JovenRESUMEN
BACKGROUND: Vivax malaria reemerged along the Demilitarized Zone (DMZ), Republic of Korea (ROK), in 1993. While it was hypothesized that vivax malaria would spread throughout the peninsula, nearly all cases were due to exposure near the DMZ. To reduce spillover of vivax malaria to the civilian community, the ROK Ministry of National Defense (MND) initiated malaria prevention policies including a large-scale chemoprophylaxis programme in malaria high-risk areas in 1997. The present study investigated the overall changes in the incidence of malaria among ROK soldiers and the mass chemoprophylaxis program from 1997 to 2016. RESULTS: Peak numbers of vivax malaria were reported in 2000, with most cases reported near the DMZ, before declining to the current levels. To combat the rapid increase in the number of malaria cases and its expansion throughout the ROK, the MND implemented mosquito control and personal protection programmes. The MND also implemented a large-scale vivax malaria chemoprophylaxis programme using hydroxychloroquine (400 mg weekly) in 1997, and primaquine (15 mg × 14 days) as terminal chemoprophylaxis in 2001. Additionally, an improved medical system enabled the rapid detection and treatment of malaria to reduce morbidity and decrease transmission of malaria from humans to mosquitoes. Following the full implementation of these programmes, the incidence of vivax malaria declined in both ROK Armed Forces and civilian populations. Subsequently, several changes in the ROK Armed Forces chemoprophylaxis programme were implemented, including the reduction of the period of hydroxychloroquine prophylaxis by 2 months (2008) and other changes in the chemoprophylaxis policy, e.g., only ROK Armed Forces personnel in moderate risk groups received terminal primaquine chemoprophylaxis (2011), and in 2016, the discontinuation of terminal primaquine chemoprophylaxis in moderate-risk area. CONCLUSIONS: The resurgence of vivax malaria in the ROK Armed Forces personnel near the DMZ was successfully suppressed through the implementation of a mass malaria chemoprophylaxis programme initiated by the MND in 1997, as well as several other factors that may have contributed to the reduction of malaria transmission since 2000. Given the current malaria situation in the ROK and North Korea, it is necessary to reevaluate the ROK Armed Forces and civilian malaria control policies.
Asunto(s)
Antimaláricos/uso terapéutico , Quimioprevención/estadística & datos numéricos , Control de Enfermedades Transmisibles/estadística & datos numéricos , Malaria Vivax/epidemiología , Personal Militar/estadística & datos numéricos , Política de Salud/legislación & jurisprudencia , Incidencia , Malaria Vivax/parasitología , Malaria Vivax/prevención & control , Plasmodium vivax/efectos de los fármacos , República de Corea/epidemiología , Factores de RiesgoRESUMEN
BACKGROUND: Although severe malaria by Plasmodium vivax has been increasingly reported, there are marked variations in the type and rate of the complications by geographic area. This is possibly because of the presence of concurrent falciparum malaria or bacteraemia, and of differences in underlying immune status among the infected subjects. Furthermore, published studies on P. vivax in temperate regions are limited. The present study investigated severe vivax malaria in Korea, where only vivax malaria occurs. Hence, other compounding factors are rare. Additionally, most of the patients are possibly non-immune to this malarial disease. METHODS: Adults with vivax malaria observed in one 860-bed university hospital from January 2006 to December 2012 were retrospectively evaluated. Seventeen patients who had travelled overseas within 6 months before the presentation of malaria were excluded. Severe vivax malaria was diagnosed according to World Health Organization criteria. Other complications were also investigated. RESULTS: Two-hundred and ten patients were enrolled, of which 88 (41.9%) were treated as inpatients and the remainder as outpatients. Eleven patients were treated in an intensive care unit; among them, five patients received mechanical ventilation, and one needed extracorporeal membrane oxygenation therapy (ECMO) additionally. Severe vivax malaria was identified in 44 patients (21.0%), and the most common severe complication was pulmonary manifestation (40/188, 21.9%), which was followed by cerebral malaria (5/210, 2.4%), shock (4/210, 1.9%), spontaneous bleeding (3/210, 1.4%), metabolic acidosis (3/210, 3.5%) and acute kidney injury (2/210, 1.0%). Unusual complications, such as splenic infarction (ten patients) and retinal haemorrhage (two patients) were sometimes observed. There were no deaths, but the case involving ECMO was potentially fatal. CONCLUSIONS: Plasmodium vivax infection can be severe to be fatal and is frequently associated with various complications in non-immune adults. The frequency of each complication seems to differ from other countries. Hence, further investigation is needed to elucidate the causes and mechanisms responsible for these differences.
Asunto(s)
Malaria Vivax/epidemiología , Plasmodium vivax/fisiología , Adolescente , Adulto , Femenino , Hospitales Universitarios , Humanos , Incidencia , Malaria Vivax/complicaciones , Malaria Vivax/parasitología , Masculino , Persona de Mediana Edad , República de Corea/epidemiología , Estudios Retrospectivos , Adulto JovenRESUMEN
We performed an in vitro cell culture experiment to ascertain whether rifampin exhibits bactericidal effects against Orientia tsutsugamushi, the causative agent of scrub typhus. ECV304 cells were infected with the Boryong or AFSC-4 strain of O. tsutsugamushi and then, the cultures were maintained in media with increasing concentrations of rifampin, azithromycin, doxycycline, or chloramphenicol for 4 days. On day 5, the media were replaced with fresh antibiotic-free medium and the cultures were maintained until day 28. On days 5, 13, and 28, immunofluorescence (IF) staining of O. tsutsugamushi was performed. IF staining on days 13 and 28 revealed increasing numbers of IF-positive foci in all cultures, even in cultures initially exposed to the highest concentration of rifampin (80 µg/mL), azithromycin (80 µg/mL), doxycycline (20 µg/mL), or chloramphenicol (100 µg/mL). The present study reveals that rifampin has no bactericidal effect against O. tsutsugamushi as observed for azithromycin, doxycycline, and chloramphenicol. A subpopulation of the bacteria that are not killed by high concentrations of the antibiotics may explain the persistence of O. tsutsugamushi in humans even after complete recovery from scrub typhus with antibiotic therapy.
Asunto(s)
Antibióticos Antituberculosos/farmacología , Orientia tsutsugamushi/efectos de los fármacos , Rifampin/farmacología , Línea Celular Tumoral , Farmacorresistencia Bacteriana , Técnica del Anticuerpo Fluorescente , Humanos , Orientia tsutsugamushi/crecimiento & desarrollo , Orientia tsutsugamushi/metabolismoRESUMEN
With increase of multi-drug resistant Escherichia coli in community-acquired urinary tract infections (CA-UTI), other treatment option with a therapeutic efficacy and a low antibiotic selective pressure is necessary. In this study, we evaluated in vitro susceptibility of E. coli isolates from CA-UTI to fosfomycin (FM), nitrofurantoin (NI), temocillin (TMO) as well as trimethoprim-sulfamethoxazole (SMX), ciprofloxacin (CIP) and cefepime (FEP). The minimal inhibitory concentrations were determined by E-test or agar dilution method according to the Clinical and Laboratory Standards Institute guidelines, using 346 E. coli collected in 12 Korean hospitals from March 2010 to February 2011. FM, NI and TMO showed an excellent susceptibility profile; FM 100% (346/346), TMO 96.8% (335/346), and NI 99.4% (344/346). Conversely, resistance rates of CIP and SMX were 22% (76/346) and 29.2% (101/349), respectively. FEP still retained an activity of 98.5%. In Korea, NI and TMO in addition to FM are a good therapeutic option for uncomplicated CA-UTI, especially for lower UTI.
Asunto(s)
Antibacterianos/administración & dosificación , Supervivencia Celular/efectos de los fármacos , Infecciones Comunitarias Adquiridas/microbiología , Infecciones por Escherichia coli/microbiología , Escherichia coli/efectos de los fármacos , Infecciones Urinarias/microbiología , Cefepima , Cefalosporinas/administración & dosificación , Ciprofloxacina/administración & dosificación , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Combinación de Medicamentos , Farmacorresistencia Bacteriana/efectos de los fármacos , Infecciones por Escherichia coli/tratamiento farmacológico , Fosfomicina/administración & dosificación , Humanos , Nitrofurantoína/administración & dosificación , Penicilinas/administración & dosificación , República de Corea , Sulfadoxina/administración & dosificación , Resultado del Tratamiento , Trimetoprim/administración & dosificación , Infecciones Urinarias/diagnósticoRESUMEN
Tsutsugamushi disease was first described in China by Hong Ge in 313. In his book Zhouhou Beiji Fang, three eschar-associated febrile diseases were described: Shashidu, Zhongxidu, and Shegongdu. Shashidu was identified as being identical to tsutsugamushi disease in Japan: it occurred in riverside areas, exhibited an eschar, and was transmitted by tiny red "sand lice". The nature of Zhongxidu remains unknown, but we propose that it is another type of Orientia tsutsugamushi infection: it occurred in mountainous areas, an eschar was observed, and the causative vector was not identified. Moreover, Zhongxidu would have predated Shashidu by five centuries; thus, the first documentation of tsutsugamushi disease would date back 2.2 millennia. O. tsutsugamushi infection without eschar has not been identified in ancient Chinese literature and may be included in Shanghan. Several ancient Chinese books describe that Shegongdu occurs following a Shegong bite. Shegong is described as a bug resembling a cockroach or cicada with a crossbow-like structure, possibly the hypostome and unfolded palps of tick, in its mouth. Thus, Shegong refers to an engorged tick and Shegongdu is a tick-borne rickettsiosis. However, due to a lack of entomological knowledge, these findings have not been recognized for the past 1.7 millennia.
RESUMEN
Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by recurrent episodes of fever accompanied by peritonitis, pleuritis, arthritis, or erysipelas-like erythema. It is known to occur mainly among Mediterranean and Middle Eastern populations such as non-Ashkenazi Jews, Arabs, Turks, and Armenians. FMF is not familiar to clinicians beyond this area and diagnosing FMF can be challenging. We report a 22-yr old boy who presented with fever, arthalgia and abdominal pain. He had a history of recurrent episodes of fever associated with arthalgia which would subside spontaneously or by antipyretics. Autosomal recessive periodic fever syndromes were suspected. Immunoglobulin D (IgD) level in the serum was elevated and DNA analysis showed complex mutations (p.Glu148Gln, p.Pro369Ser, p.Arg408Gln) in the MEFV gene. 3D angio computed tomography showed total thrombosis of splenic vein with partial thrombosis of proximal superior mesenteric vein, main portal vein and intrahepatic both portal vein. This is a case of FMF associated with multiple venous thrombosis and elevated IgD level. When thrombosis is associated with elevated IgD, FMF should be suspected. This is the first adult case reported in Korea.
Asunto(s)
Fiebre Mediterránea Familiar/diagnóstico , Inmunoglobulina D/sangre , Deficiencia de Mevalonato Quinasa/diagnóstico , Trombosis de la Vena/diagnóstico , Dolor Abdominal/etiología , Artralgia/etiología , Proteínas del Citoesqueleto/genética , Proteínas del Citoesqueleto/metabolismo , Fiebre Mediterránea Familiar/complicaciones , Humanos , Masculino , Venas Mesentéricas , Deficiencia de Mevalonato Quinasa/complicaciones , Mutación , Vena Porta , Pirina , República de Corea , Vena Esplénica , Tomografía Computarizada por Rayos X , Trombosis de la Vena/complicaciones , Adulto JovenRESUMEN
Complicated malaria is mainly caused by Plasmodium falciparum, but, increasingly, Plasmodium vivax is also being reported as a cause. Since the reemergence of indigenous vivax malaria in 1993, cases of severe malaria have been steadily reported in Korea. Herein, we report a case of vivax malaria complicated by adult respiratory distress syndrome (ARDS) that was successfully managed with extracorporeal membrane oxygenation (ECMO). A 59-year-old man presented at our hospital with fever and abdominal pain, which had persisted for 10 days. On admission, the patient had impaired consciousness, shock, hypoxia and haziness in both lungs, jaundice, thrombocytopenia and disseminated intravascular coagulation, metabolic acidosis, and acute kidney injury. A peripheral blood smear and a rapid diagnostic test verified P. vivax mono-infection. Ten hours after admission, hypoxia became more severe, despite providing maximal ventilatory support. The administration of antimalarial agents, ECMO, and continuous venovenous hemofiltration resulted in an improvement of his vital signs and laboratory findings. He was discharged from the hospital 7 weeks later, without any sequelae.
Asunto(s)
Antimaláricos/administración & dosificación , Malaria Vivax/complicaciones , Plasmodium vivax/aislamiento & purificación , Síndrome de Dificultad Respiratoria/complicaciones , Lesión Renal Aguda , Oxigenación por Membrana Extracorpórea , Humanos , Hipoxia , Pulmón/diagnóstico por imagen , Malaria Vivax/diagnóstico , Malaria Vivax/diagnóstico por imagen , Malaria Vivax/terapia , Masculino , Persona de Mediana Edad , Insuficiencia Multiorgánica , Radiografía , República de Corea , Síndrome de Dificultad Respiratoria/diagnóstico por imagen , Síndrome de Dificultad Respiratoria/terapia , Resultado del TratamientoRESUMEN
Scrub typhus can be adequately treated with doxycycline or azithromycin unless it is treated too late. Such cases present as severe scrub typhus, and their treatment remains a challenging problem. In this article, we briefly review the literature on the treatment of scrub typhus and the limitations of the combination of doxycycline and azithromycin. Several options are suggested for further study in the treatment of severe scrub typhus (such as encephalitis, myocarditis, and pneumonia), including dose escalation of doxycycline, the adjuvant use of steroids, the selective use of beta-lactam antibiotics, and the use of tigecycline.
RESUMEN
We investigated the persistence of viable Orientia tsutsugamushi in patients who had recovered from scrub typhus. Blood specimens were available from six patients with scrub typhus who were at 1 to 18 months after the onset of the illness. The EDTA-treated blood specimens were inoculated into ECV304 cells, and cultures were maintained for 7 months. Sequencing of the 56-kDa type-specific antigen gene of O. tsutsugamushi was performed to ascertain the homology of isolates. O. tsutsugamushi was isolated from all six patients, and nucleotide sequences of isolates serially collected from each patient were identical in all five patients in whom nucleotide sequences were compared. One patient relapsed 2 days after completion of antibiotic therapy; two patients complained of weakness for 1 to 2.5 months after the illness; one patient underwent coronary angioplasty 6 months later; and one patient suffered from a transient ischemic attack 8 months later. This finding suggests that O. tsutsugamushi causes chronic latent infection, which may be associated with certain clinical illnesses, preceded by scrub typhus. Antibiotic therapy abates the symptoms of scrub typhus, but does not eradicate O. tsutsugamushi from the human body.
Asunto(s)
Orientia tsutsugamushi/aislamiento & purificación , Tifus por Ácaros/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Antígenos Bacterianos/genética , Proteínas Bacterianas/genética , Secuencia de Bases , Estudios de Casos y Controles , Enfermedad Crónica , Enfermedad de la Arteria Coronaria/etiología , ADN Bacteriano/genética , ADN Bacteriano/aislamiento & purificación , Femenino , Genes Bacterianos , Humanos , Ataque Isquémico Transitorio/etiología , Masculino , Proteínas de la Membrana/genética , Persona de Mediana Edad , Debilidad Muscular/etiología , Orientia tsutsugamushi/genética , Orientia tsutsugamushi/inmunología , Recurrencia , Tifus por Ácaros/complicaciones , Tifus por Ácaros/tratamiento farmacológico , Factores de TiempoRESUMEN
The efficacy and safety of ertapenem, 1 g once daily, were compared with that of ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) and complicated urinary tract infections (cUTIs) in a prospective, multicenter, double-blinded, randomized study. After ≥ 3 days of parenteral study therapy, patients could be switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or other cUTIs (n = 61), 66 (48.9%) in the ertapenem group and 71 (52.2%) in the ceftriaxone group were microbiologically evaluable. The mean duration of parenteral and total therapy, respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. The most common pathogen was Escherichia coli. At the primary efficacy endpoint 5-9 days after treatment, 58 (87.9%) patients in the ertapenem group and 63 (88.7%) in the ceftriaxone had a favorable microbiological response. When compared by stratum and severity, the outcomes in the two groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. The results indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs.
Asunto(s)
Antibacterianos/uso terapéutico , Ceftriaxona/uso terapéutico , Pielonefritis/tratamiento farmacológico , Infecciones Urinarias/tratamiento farmacológico , beta-Lactamas/uso terapéutico , Enfermedad Aguda , Método Doble Ciego , Ertapenem , Humanos , Oportunidad Relativa , Pielonefritis/complicaciones , República de Corea , Factores de Riesgo , Infecciones Urinarias/complicacionesRESUMEN
Buerger's disease (BD) is a chronic inflammatory vasculitis of unknown etiology. The infectious etiology of BD was proposed by Buerger in 1914. Furthermore, there are scattered reports insisting that BD may be related to rickettsial infection, first asserted by Goodman since 1916, followed by Giroud and other French investigators from the 1940s through the 1960s, Nicolau in the 1960s, Bartolo (1980s), and Fazeli (2010s). However, their causal relationship has hardly been accepted because rickettsial infections are known to be acute febrile, vector-borne illnesses, whereas BD is a chronic afebrile illness. In this article we review the relevant literature on the chronic nature of Rickettsia and Orientia infections and on the rickettsial etiology of BD. Excellent initial responses to doxycycline in three patients with BD are briefly described. Based on these findings, we hypothesize that BD patients acquired a rickettsial infection far before the onset of BD. Over years, the infected area expands to become a segment of the infected vessel. Subsequently, thrombus develops on the luminal surface of the infected endothelial cells, which produces the vascular obstructive manifestations of BD. Collectively, it is postulated that BD is a chronic infection with a member of the family Rickettsiaceae with superimposed thrombosis.
RESUMEN
Triboelectric nanogenerators (TENGs) based on ferroelectric organic materials have advantages of high flexibility, biocompatibility, controllable ferroelectric properties, etc. However, this has limited the electrical output performance due to their lower ferroelectric characteristics than those of inorganic ferroelectric materials. A lot of effort has been made to improve the organic ferroelectric characteristics through composites, surface modifications, structures, etc. Herein, we report TENGs made of ferroelectric composite materials consisting of poly(vinylidene fluoride-co-trifluoroethylene) (PVDF-TrFE) and poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS). The composite was prepared by simply blending PVDF-TrFE and PEDOT:PSS with a weight ratio from 0% to 60%. When the ratio was 20%, the ferroelectric-crystalline phase was enhanced and the highest dielectric constant was observed. Accordingly, the TENGs consisting of 20% composite film and polyimide exhibited the best output performance: the maximum open circuit voltage and short circuit current were â¼15 V and â¼2.3 µA at 1 Hz oscillation, respectively. These results indicate that the ferroelectric characteristics of PVDF-TrFE can be enhanced by adding PEDOT:PSS as a nanofiller.
RESUMEN
This study introduces localized surface plasmon resonance (L-SPR) mediated heating filter membrane (HFM) for inactivating universal viral particles by using the photothermal effect of plasmonic metal nanoparticles (NPs). Plasmonic metal NPs were coated onto filter membrane via a conventional spray-coating method. The surface temperature of the HFM could be controlled to approximately 40-60 °C at room temperature, owing to the photothermal effect of the gold (Au) NPs coated on them, under irradiation by visible light-emitting diodes. Due to the photothermal effect of the HFMs, the virus titer of H1Npdm09 was reduced by > 99.9%, the full inactivation time being < 10 min, confirming the 50% tissue culture infective dose (TCID50) assay. Crystal violet staining showed that the infectious samples with photothermal inactivation lost their infectivity against Mardin-Darby Canine Kidney cells. Moreover, photothermal inactivation could also be applied to reduce the infectivity of SARS-CoV-2, showing reduction rate of 99%. We used quantitative reverse transcription polymerase chain reaction (qRT-PCR) techniques to confirm the existence of viral genes on the surface of the HFM. The results of the TCID50 assay, crystal violet staining method, and qRT-PCR showed that the effective and immediate reduction in viral infectivity possibly originated from the denaturation or deformation of membrane proteins and components. This study provides a new, simple, and effective method to inactivate viral infectivity, leading to its potential application in various fields of indoor air quality control and medical science.
Asunto(s)
COVID-19/virología , Calor , Luz , Nanopartículas del Metal , Filtros Microporos , SARS-CoV-2 , Resonancia por Plasmón de Superficie/métodos , Virión , Inactivación de Virus , Contaminación del Aire Interior , Animales , Células Cultivadas , Perros , Oro/química , SARS-CoV-2/genética , SARS-CoV-2/patogenicidadRESUMEN
ABSTRACT: Epstein-Barr virus (EBV) is frequently reactivated by coronavirus 2019 (COVID-19), and a high incidence of EBV viremia has been reported in patients with severe COVID-19. However, the impact of EBV viremia on progression to severe COVID-19 is unclear. Therefore, we conducted a study to evaluate the effect of EBV on COVID-19 progression.We investigated EBV viremia at the time of admission in COVID-19 patients hospitalized between February 1, 2020, and April 11, 2021. A cross-sectional study was performed to compare the severity of COVID-19 according to the presence or absence of EBV viremia. However, since it is difficult to analyze the influence of EBV viremia on COVID-19 progression with cross-sectional studies, a retrospective cohort study, limited to patients with mild COVID-19, was additionally conducted to observe progression to severe COVID-19 according to the presence or absence of EBV viremia.Two hundred sixty-nine COVID-19 patients were tested for EBV viremia. In a cross-sectional study that included patients with both mild and severe COVID-19, the EBV viremia group had more severe pneumonia than the EBV-negative group. However, in the cohort study limited to mild cases (Nâ=â213), EBV viremia was not associated with COVID-19 progression.COVID-19 severity may affect EBV viremia; however, there was no evidence that EBV viremia was a factor in exacerbating pneumonia in patients with mild COVID-19.